Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $55.83.
Separately, Needham & Company LLC reissued a “buy” rating and issued a $55.00 price target on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th.
View Our Latest Research Report on Rhythm Pharmaceuticals
Insider Buying and Selling at Rhythm Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. raised its holdings in Rhythm Pharmaceuticals by 809.2% in the fourth quarter. Victory Capital Management Inc. now owns 182,297 shares of the company’s stock worth $8,380,000 after purchasing an additional 162,247 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Rhythm Pharmaceuticals by 3.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 397,685 shares of the company’s stock valued at $18,282,000 after acquiring an additional 12,937 shares during the period. BNP Paribas Financial Markets boosted its stake in Rhythm Pharmaceuticals by 14.2% during the fourth quarter. BNP Paribas Financial Markets now owns 63,085 shares of the company’s stock worth $2,900,000 after acquiring an additional 7,842 shares in the last quarter. Jump Financial LLC purchased a new stake in Rhythm Pharmaceuticals in the fourth quarter worth about $588,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $234,000.
Rhythm Pharmaceuticals Stock Performance
Shares of Rhythm Pharmaceuticals stock opened at $49.31 on Tuesday. The firm has a market capitalization of $3.01 billion, a PE ratio of -10.56 and a beta of 2.07. Rhythm Pharmaceuticals has a 12 month low of $20.97 and a 12 month high of $53.92. The business’s 50-day moving average price is $47.14 and its 200-day moving average price is $42.78.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The firm had revenue of $29.08 million for the quarter, compared to the consensus estimate of $28.79 million. During the same period last year, the firm posted ($0.82) earnings per share. The business’s revenue was up 51.3% compared to the same quarter last year. As a group, analysts predict that Rhythm Pharmaceuticals will post -4.44 earnings per share for the current fiscal year.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Featured Articles
- Five stocks we like better than Rhythm Pharmaceuticals
- Canadian Penny Stocks: Can They Make You Rich?
- 3 Leveraged ETFs to Multiply Returns
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Golden Cross Stocks: Pattern, Examples and Charts
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.